Company intelligence / Profile preview
Ruiyang Pharmaceutical
Zhanjiang, Guangdong, Chinareyoung.com ↗
- Ownership
- Private
- Employees
- ~4000
- Development stage
- Other
01
Overview
Ruiyang has several approved drugs globally, with others in late-stage clinical trials. Notable approvals include mezlocillin sodium monohydrate for gram-negative bacterial infections. Other programs are at NDA/BLA or Phase III stages targeting infectious diseases and functional disorders.
- Therapeutic areas
- Women's HealthGastroenterologyInfectious Diseases
- Modalities
- Small moleculeHerbal medicineBiological productsFusion protein
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Ruiyang Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ruiyang Pharmaceutical.